Ischemic Stroke News and Research

RSS

No time to lose in basilar artery occlusion treatment

Patients with basilar artery occlusion should undergo recanalization therapy as soon as possible, show data from BASICS.

24 Sep 2012

Routine tests flag up cancer danger in cryptogenic stroke

Blood tests and imaging findings could point to hidden malignancies in patients with cryptogenic stroke, say researchers.

21 Sep 2012

Routine tests flag up cancer danger in cryptogenic stroke

Blood tests and imaging findings could point to hidden malignancies in patients with cryptogenic stroke, say researchers.

21 Sep 2012

Silent infarcts prognostic in young stroke patients

Silent ischemic lesions are common and are associated with a high rate of recurrent events in young patients with acute ischemic stroke, report researchers.

12 Sep 2012

Florida Hospital Tampa adopts FDA approved Trevo Pro Clot Retriever

Florida Hospital Tampa and Dr. James E. Lefler are the first in the Tampa Bay area to adopt the new FDA approved device called the Trevo Pro Clot Retriever manufactured by Stryker. The Trevo Pro is the next generation in clot removal technology.

10 Sep 2012

Dabigatran exposure may RE-LY on genetics

Researchers have found that variants in the ABCB1 and CES1 genes are associated with increased dabigatran plasma levels in patients taking the oral anticoagulant.

30 Aug 2012

Risk of stroke after myocardial infarction seems to decrease with improvements in coronary care

The analysis of data from two Swedish registries was presented by Dr Anders Ulvenstam, and suggests that the reduction is due to improvements in AMI care.

29 Aug 2012

Resuming smoking after stroke can increase risk of mortality

Patients who resume smoking after a stroke increase their risk of death by three-fold, according to research presented at ESC Congress 2012 by Professor Furio Colivicchi from San Filippo Neri Hospital.

28 Aug 2012

Trevo Retriever effectively removes blood clots in patients with stroke

Every 40 seconds, someone in the United States has a stroke, usually caused when a clot blocks an artery that supplies blood to the brain. Now the results of two multicenter studies published online in The Lancet on August 26 are giving physicians new innovative tools proven to better remove these clots that block blood flow.

26 Aug 2012

Confocal light sheet microscopy yields high-resolution views of brain’s neural pathways

Shortly after the Hubble Space Telescope went into orbit in 1990 it was discovered that the craft had blurred vision. Fortunately, Space Shuttle astronauts were able to remedy the problem a few years later with supplemental optics. Now, a team of Italian researchers has performed a similar sight-correcting feat for a microscope imaging technique designed to explore a universe seemingly as vast as Hubble's but at the opposite end of the size spectrum—the neural pathways of the brain.

24 Aug 2012

OBI’s Oxycyte improves imaging of penumbra following acute ischemic stroke

Oxygen Biotherapeutics, Inc., announced today that recent research conducted by its partner, Aurum Biosciences, Glasgow, Scotland, has shown that Oxycyte, OBI's proprietary perfluorocarbon-based intravenous emulsion, improves imaging of the penumbra following acute ischemic stroke in a rat model.

22 Aug 2012

FDA clears Stryker’s Trevo Pro Retriever to treat acute ischemic stroke

Stryker Neurovascular announced today that its Trevo Pro Retriever has been granted 510(k) market clearance by the U.S. Food and Drug Administration. The Trevo Pro Retriever is the next generation in clot removal technology from Stryker, utilizing proprietary Stentriever Technology for optimized clot integration and retrieval in patients experiencing acute ischemic stroke.

From Stryker 13 Aug 2012

Clinical trials to test safety of 3K3A-APC in patients with ischemic stroke

Clinical trials start this week for a stroke drug initially created by a team led by scientists at The Scripps Research Institute and the University of Southern California (USC), and further developed by biotech company ZZ Biotech.

9 Aug 2012

Working outside 9-5 shifts vascular risk

People who undertake shift work may be at a higher risk for vascular events than those who do not, researchers say in the BMJ.

31 Jul 2012

PRACTISE saves money in stroke care

The PRACTISE intervention to boost stroke thrombolysis rates is not just cost-effective, but cost-saving, show the results of a prespecified analysis.

25 Jul 2012

Covidien receives Brazilian approval for Solitaire FR Revascularization Device

Covidien, a leading global provider of healthcare products, today announced that the Solitaire FR Revascularization Device has been approved by Brazil's National Health Surveillance Agency. The Solitaire FR device is used to restore blood flow to the brain in patients suffering acute ischemic stroke.

20 Jul 2012

Adding stroke severity in hospital mortality model may improve prediction of death risk

Adding stroke severity to a hospital 30-day mortality model based on claims data for Medicare beneficiaries with acute ischemic stroke was associated with improvement in predicting the risk of death at 30 days and changes in performance ranking regarding mortality for a considerable proportion of hospitals, according to a study in the July 18 issue of JAMA.

18 Jul 2012

Jade, BioTime sign exclusive sublicense and supply agreement for HyStem

BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement and a supply agreement with Jade Therapeutics, LLC, a developer of an ophthalmological therapeutic sustained-release drug delivery platform.

18 Jul 2012

Combination of tPA and 3K3A-APC may effectively treat stroke

A team led by a physician-scientist at the University of Southern California (USC) has created an experimental drug that reduces brain damage and improves motor skills among stroke-afflicted rodents when given with federally approved clot-busting therapy.

18 Jul 2012

AstraZeneca plans to conduct ticagrelor plus clopidogrel clinical trial for PAD

AstraZeneca today announced plans to conduct the EUCLID study, a global clinical trial involving 11,500 patients with peripheral artery disease (PAD), a condition affecting approximately 27 million people in Europe and North America.

17 Jul 2012